Role of rifampin for treatment of orthopedic implant-related staphylococcal infections: a randomized controlled trial. Foreign-Body Infection (FBI) Study Group.
Clin Infect Dis. 2002;34(11):1481.
Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections.
Clin Infect Dis. 2005;40(11):1601.
Telavancin versus standard therapy for treatment of complicated skin and soft-tissue infections due to gram-positive bacteria.
Clin Infect Dis. 2005;41(10):1407.
Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections.
Clin Infect Dis. 2005;40(3):374.
Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by gram-positive pathogens.
N Engl J Med. 2006;355(7):653.
Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus.
Daptomycin (6 mg per kilogram daily) is not inferior to standard therapy for S. aureus bacteremia and right-sided endocarditis.
Antimicrob Agents Chemother. 2006;50(3):862.
Telavancin versus standard therapy for treatment of complicated skin and skin structure infections caused by gram-positive bacteria: FAST 2 study
Clin Infect Dis. 2008;46(11):1683.
Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms.
Clin Infect Dis. 2008;46(5):647.
A randomized, double-blind trial comparing ceftobiprole medocaril with vancomycin plus ceftazidime for the treatment of patients with complicated skin and skin-structure infections.
Antimicrob Agents Chemother. 2008;52(1):37.
Results of a double-blind, randomized trial of ceftobiprole treatment of complicated skin and skin structure infections caused by gram-positive bacteria.
J Antimicrob Chemother. 2008;61(1):177.
Outcomes with daptomycin versus standard therapy for osteoarticular infections associated with Staphylococcus aureus bacteraemia.
Daptomycin may be considered an alternative to standard therapy in the treatment of patients with complicated SAB and OAI.
Clin Infect Dis. 2010;51(6):641.
Integrated analysis of CANVAS 1 and 2: phase 3, multicenter, randomized, double-blind studies to evaluate the safety and efficacy of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin-structure infection.
JAMA. 2013 Feb;309(6):559-69.
Tedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure infections: the ESTABLISH-1 randomized trial.
Lancet Infect Dis. 2014;14(8):696.
Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2): a randomised, double-blind, phase 3, non-inferiority trial.
Antimicrob. Agents Chemother. 2014 Nov; 58(11):6518-27.
Safety, tolerability, and efficacy of GSK1322322 in the treatment of acute bacterial skin and skin structure infections.
results will be used to guide dose selection in future studies with GSK1322322 to optimize its tolerability and efficacy in patients with acute bacterial skin and skin structure infections (ABSSSIs)
BMC Infect. Dis. 2014.:183
Effect of vancomycin serum trough levels on outcomes in patients with nosocomial pneumonia due to Staphylococcus aureus: a retrospective, post hoc, subgroup analysis of the Phase 3 ATTAIN studies
N Engl J Med. 2014;370(23):2169.
Once-weekly dalbavancin versus daily conventional therapy for skin infection.
Once-weekly intravenous dalbavancin was not inferior to twice-daily intravenous vancomycin followed by oral linezolid for the treatment of acute bacterial skin and skin-structure infection.
N Engl J Med. 2014;370(23):2180.
Single-dose oritavancin in the treatment of acute bacterial skin infections.
A single dose of oritavancin was noninferior to twice-daily vancomycin administered for 7 to 10 days for the treatment of acute bacterial skin and skin-structure infections caused by gram-positive pathogens.
Clin Infect Dis. 2015;60(2):254.
Single-dose oritavancin versus 7-10 days of vancomycin in the treatment of gram-positive acute bacterial skin and skin structure infections: the SOLO II noninferiority study.
A single 1200-mg dose of oritavancin was noninferior to 7-10 days of vancomycin in treating ABSSSIs caused by gram-positive pathogens, and was well tolerated. Oritavancin provides a single-dose alternative to multidose therapies for the treatment of ABSSSIs.
J Antimicrob Chemother. 2015 Jan; 70(1):264-72.
Randomized non-inferiority trial to compare trimethoprim/sulfamethoxazole plus rifampicin versus linezolid for the treatment of MRSA infection.
Compared with linezolid, trimethoprim/sulfamethoxazole and rifampicin seems to be non-inferior in the treatment of MRSA infection.
Trimethoprim-sulfamethoxazole versus vancomycin for severe infections caused by meticillin resistant Staphylococcus aureus: randomised controlled trial.
High dose trimethoprim-sulfamethoxazole did not achieve non-inferiority to vancomycin in the treatment of severe MRSA infections
N Engl J Med. 2015 Mar 19; 372(12):1093-103
Clindamycin versus trimethoprim-sulfamethoxazole for uncomplicated skin infections.
We found no significant difference between clindamycin and TMP-SMX, with respect to either efficacy or side-effect profile, for the treatment of uncomplicated skin infections, including both cellulitis and abscesses.